CMRX Chimerix Inc.: רווח למניה ב-12 החודשים האחרונים

Chimerix, Inc. (CMRX) possesses high scaling potential following FDA approval due to low-cost molecule synthesis. The business relies on government contracts for antivirals and the treatment of rare tumors. However, the sustainability of its economic moat depends on the outcome of Phase III trials. Relative EPS YoY growth over the last 12 months helps filter out market noise, and -154.50 expresses the current value of this metric.

The indicator calculates the net income per share dynamics over a rolling year, reacting promptly to every earnings update. This metric eliminates quarterly gaps, allowing for the tracking of the real growth rate of profitability without emotional distortions. For Chimerix, Inc. (CMRX), amid the expansion of the oncology drug market and stable government contracts, this parameter reflects the efficiency of molecule commercialization. Analyzing comparable annual EPS TTM growth helps identify whether the asset is overvalued. Investors must correlate this trend with the macroeconomic backdrop.